← Leaderboards
Stephen L Lessnick
Dana-Farber Cancer Institute
$7,170,581
Attributed
$7,973,476
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9.7M · FY2005–22$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$14,136,961 · 8
By mechanism
U54$9,707,609 · 3
R01$2,724,846 · 2
K08$679,176 · 1
R21$656,240 · 1
T32$369,090 · 1
Top collaborators
- Sunil Sharma4 shared
- Timothy P Cripe1 shared
Most similar at Dana-Farber Cancer Institute
Same institution · by research overlap
- A Thomas Look$30,189,128
- Scott A Armstrong$21,470,003
- James L M Ferrara$21,206,325
- Ellis L Reinherz$59,058,313
- Thomas S. Kupper$36,607,647
Others in their field
Top investigators on “Cell Line”
- David Heimbrook · Leidos Biomedical Research, Inc.$236,973,333
- Dennis R. Burton · Scripps Research Institute$203,685,614
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$177,001,772
- John M Lachin · George Washington University$118,672,444
- David M Nathan · Massachusetts Institute Of Technology$118,672,444
- Fred M Gordin · Social And Scientific Systems, Inc.$82,802,056
Research focus
Cell LineEwings SarcomaBaseGene ExpressionCellsMalignant NeoplasmsGenesOncogenicLinkMediatingTranscription FactorGene RepressionGene TargetingGenetic TranscriptionChildTranscription CoactivatorEventProteinsChimeric ProteinsTranscription Repressor/CorepressorPhenotypeMalignant - DescriptorBonePathway Interactions
Grant awards (24)
Training Program in Basic and Translational Pediatric Oncology Research$369,090
T32 · FY2022 · CA · contact PI
An integrated approach to analyze and target EWS/FLI in Ewing sarcoma$6,163,485
U54 · FY2018 · CA · contact PI
Project 1: The Interplay Between EWS/FLI and GGAA-Microsatellites in Ewing Sarcoma$2,667,462
U54 · FY2018 · CA · contact PI
Admin Core - A$876,662
U54 · FY2018 · CA · contact PI
(PQB-2) "Driver" vs. "passenger" epigenetic events in Ewing sarcoma$309,175
R01 · FY2017 · CA · contact PI
(PQB-2) "Driver" vs. "passenger" epigenetic events in Ewing sarcoma$309,175
R01 · FY2016 · CA · contact PI
(PQB-2) "Driver" vs. "passenger" epigenetic events in Ewing sarcoma$309,175
R01 · FY2015 · CA · contact PI
(PQB-2) "Driver" vs. "passenger" epigenetic events in Ewing sarcoma$309,175
R01 · FY2014 · CA · contact PI
EWS/FLI AND ITS TARGETS IN EWING'S SARCOMA$216,403
R01 · FY2014 · CA · contact PI
EWS/FLI AND ITS TARGETS IN EWING'S SARCOMA$74,750
R01 · FY2014 · CA · contact PI
EWS/FLI AND ITS TARGETS IN EWING'S SARCOMA$282,222
R01 · FY2013 · CA · contact PI
EWS/FLI AND ITS TARGETS IN EWING'S SARCOMA$300,906
R01 · FY2012 · CA · contact PI
EWS/FLI AND ITS TARGETS IN EWING'S SARCOMA$301,577
R01 · FY2011 · CA · contact PI
Antibody-based detection of translocations in pediatric cancer$192,700
R21 · FY2011 · CA · contact PI
EWS/FLI AND ITS TARGETS IN EWING'S SARCOMA$312,288
R01 · FY2010 · CA · contact PI
Antibody-based detection of translocations in pediatric cancer$231,770
R21 · FY2010 · CA · contact PI
Antibody-based detection of translocations in pediatric cancer$231,770
R21 · FY2009 · CA · contact PI
Tumor Suppressors in Ewing's Sarcoma$67,918
K08 · FY2007 · CA · contact PI
Tumor Suppressors in Ewing's Sarcoma$135,837
K08 · FY2006 · CA · contact PI
Tumor Suppressors in Ewing's Sarcoma$135,837
K08 · FY2005 · CA
Tumor Suppressors in Ewing's Sarcoma$135,711
K08 · FY2004 · CA
Tumor Suppressors in Ewing's Sarcoma$117
K08 · FY2004 · CA
Tumor Suppressors in Ewing's Sarcoma$135,837
K08 · FY2003 · CA
Tumor Suppressors in Ewing's Sarcoma$67,919
K08 · FY2002 · CA